How Sahm Adrangi Makes Money Shorting Company Stocks

Sahm Adrangi is a professional in the financial industry in New York City. After earning his economics degree at Yale University he worked for some of the largest firms no Wall Street such as Deutsche Bank, Longacre Fund Management LLC, and Chanin Capital Partners. He was an analyst for these three firms and worked for them at different times over the course of five years. While working as an analyst he developed deep experience in areas such as leveraged financing, bankruptcy restructuring, and distressed debt.

It was in 2009 that Sahm Adrangi struck out on his own as an entrepreneur. He launched Kerrisdale Capital Management LLC in April of that year. Serving as the Chief Investment Officer, he manages the firm’s investments, overall strategies, and all other aspects of running the company, and Sahm Adrangi’s lacrosse camp.

One of Sahm Adrangi’s biggest specialties is researching companies. From performing this research, which he also publishes, he knows whether to buy or short a company’s stocks. He has been very successful shorting firms. In particular, a number of years ago his research showed him that a group of Chinese companies were fraudulent. He shorted their stock before releasing his research. When it was shown that he was right he made quite a bit of money for Kerrisdale Capital.

Making perhaps the biggest stake in his career, In April 2016 Sahm Adrangi shorted the stock of a $10+ billion American company. He successfully raised $100 million from other investors when he showed them his convincing research that the company was very much overvalued. In order to provide his research to investors, he and one of his analysts prepared a report that was backed up by a video and a website outlining his research, and Sahm Adrangi on Facebook.

At Kerrisdale Management, Sahm Adrangi has led the company to having about $500 million in assets under management. Some of this came from his willingness to short the stock of two pharmaceutical companies, Zafgen and Sage Therapeutics. He also shorted the stock of Globalstar, a satellite company, in recent years successfully as well.

Leave a Reply

Your email address will not be published. Required fields are marked *